Quantcast

Latest Clinical trial Stories

2014-10-17 16:24:18

BALTIMORE, Md., Oct. 17, 2014 /PRNewswire-USNewswire/ -- The following is being released by the Center for Medical Technology Policy: The Green Park Collaborative (GPC) will bring together representatives from the FDA, public and private payers, medical device and pharmaceutical companies, as well as patient representatives, clinicians, and other experts January 12, 2015 at its first ever workshop on the comparative effectiveness and value of weight loss treatments. Participants...

2014-10-17 12:29:40

DUBLIN, October 17, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/6cbkgn/latest_guidebook) has announced the addition of the "Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition)" [http://www.researchandmarkets.com/research/6cbkgn/latest_guidebook ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769...

2014-10-16 23:13:25

Synergy Selects ClinCapture as its Electronic Data Capture (EDC) For Its Ease Of Use and Advanced Functionality Sunnyvale, CA (PRWEB) October 16, 2014 Silicon Valley Electronic Data Capture (EDC) provider Clinovo joins forces with Synergy Research group, the leading clinical organization in the Russian region. Clinovo’s electronic data capture (EDC) system ClinCapture will be used to streamline data capture at Synergy’s clinical research facilities in Russia, Ukraine, Kazakhstan,...

2014-10-15 23:06:56

Clinical Conductor CTMS is now fitted with new and enhanced functionality set to optimize the way organizations conduct complex oncology clinical research. Rochester, NY (PRWEB) October 15, 2014 The team behind Clinical Conductor is proud to announce brand new enhancements to the industry-leading CTMS. This first oncology focused release of several in the coming quarters adds a multitude of advanced features and functionalities designed to optimize the management and execution of oncology...

2014-10-15 08:29:30

BUFFALO, N.Y., Oct. 15, 2014 /PRNewswire/ -- Hanmi Pharmaceuticals and Collaborative Partner Kinex Pharmaceuticals announce today preliminary results from a Phase I Clinical Study of Oratecan - an oral form of the approved intravenously administered cancer drug irinotecan, with HM30181, a potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. Irinotecan is a type 1 DNA topoisomerase inhibitor, marketed under the trade name Camptosar. It is approved for the...

2014-10-14 08:34:17

First Patient Has Begun Treatment Process; Additional Patients Being Assessed; Waiting List Established BETHESDA, Md., Oct. 14, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the DCVax-L Hospital Exemption Program that was approved by the German regulatory authority earlier this year is now under way. The first patient with Glioblastoma...

2014-10-14 04:22:26

KALAMAZOO, MI and KATOWICE, Poland, Oct. 14, 2014 /PRNewswire/ -- Ablative Solutions, Inc. (ASI), a privately held company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has treated the first patient in the Peregrine Study. Patients enrolled in the study receive targeted therapy using the investigational Peregrine System(TM) Infusion Catheter to treat sympathetic nerves located in the outer region of arteries. The interruption of these nerve...

2014-10-13 12:26:55

MONT-SAINT-GUIBERT, Belgium, October 13, 2014 /PRNewswire/ -- - CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart failure - To date, 12 countries have granted authorization for Cardio3 BioSciences' Phase III (CHART-1) - The progress of CHART-1 is in line with objectives Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a...

2014-10-13 12:26:17

DUBLIN, Oct. 13, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Nonalcoholic Steatohepatitis (NASH) also known as silent disease is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are...

2014-10-12 23:01:50

MarketOptimizer.org adds “Ventricular Septal Defect Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Ventricular Septal Defect. Dallas, Texas (PRWEB) October 12, 2014 A ventricular septal defect (VSD) is a defect in the ventricular septum, the wall dividing the left and right ventricles of the heart. The ventricular septum consists of an inferior muscular and superior membranous portion and is...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related